KEI Briefing Note 2021:2 Canadian Experience with Compulsory Licensing under the Canadian Access to Medicines Regime
KEI Briefing Note
KEI Briefing Note 2021:1 Comments on the Proposal to Eliminate Unreasonable Prices as a Standalone Basis for March-in Rights (Modify 37 CFR § 401.6)
Comments on the Proposal to Eliminate Unreasonable Prices as a Standalone Basis for March-in Rights (Modify 37 CFR § 401.6) KEI Briefing Note 2021:1 March 18, 2021 James Love (Note: The contents of this briefing note were submitted to the… Continue Reading
KEI Briefing Note 2017:1. Bayh-Dole Act and difference between March-In Rights and the world wide royalty free rights in patents
Bayh-Dole Act and difference between March-In Rights and the world wide royalty free rights in patents KEI Briefing Note 2017:1 When the United States federal government funds research that results in patents, it obtains rights, either directly or through contracts,… Continue Reading